PRCT Key Statistics, Chart & Performance
The current stock price of PRCT is 35.72 USD. In the past month the price increased by 13.12%. In the past year, price decreased by -60.78%.
PRCT Latest News, Press Relases and Analysis
PRCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.56 | 213.10B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.56 | 197.05B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.41 | 137.38B | ||
| SYK | STRYKER CORP | 26.86 | 135.27B | ||
| IDXX | IDEXX LABORATORIES INC | 55.69 | 56.08B | ||
| BDX | BECTON DICKINSON AND CO | 13.76 | 56.62B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.65 | 48.69B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.4 | 38.47B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| DXCM | DEXCOM INC | 36.32 | 26.35B | ||
| PODD | INSULET CORP | 64.57 | 20.76B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.51 | 18.45B |
Related stock screener links
About PRCT
Company Profile
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 756 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Company Info
PROCEPT BIOROBOTICS CORP
150 Baytech Drive
San Jose CALIFORNIA US
CEO: Reza Zadno
Employees: 756
Phone: 16502329832
PROCEPT BIOROBOTICS CORP / PRCT FAQ
What does PRCT do?
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 756 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
What is the stock price of PROCEPT BIOROBOTICS CORP today?
The current stock price of PRCT is 35.72 USD. The price increased by 2.06% in the last trading session.
Does PRCT stock pay dividends?
PRCT does not pay a dividend.
What is the ChartMill rating of PROCEPT BIOROBOTICS CORP stock?
PRCT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting PRCT stock to perform?
19 analysts have analysed PRCT and the average price target is 54.8 USD. This implies a price increase of 53.42% is expected in the next year compared to the current price of 35.72.
Can you provide the PE ratio for PRCT stock?
PROCEPT BIOROBOTICS CORP (PRCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
Can you provide the ownership details for PRCT stock?
You can find the ownership structure of PROCEPT BIOROBOTICS CORP (PRCT) on the Ownership tab.
PRCT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PRCT. When comparing the yearly performance of all stocks, PRCT is a bad performer in the overall market: 91.21% of all stocks are doing better.
PRCT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PRCT. While PRCT seems to be doing ok healthwise, there are quite some concerns on its profitability.
PRCT Financial Highlights
Over the last trailing twelve months PRCT reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 21.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.53% | ||
| ROE | -22.24% | ||
| Debt/Equity | 0.14 |
PRCT Forecast & Estimates
19 analysts have analysed PRCT and the average price target is 54.8 USD. This implies a price increase of 53.42% is expected in the next year compared to the current price of 35.72.
For the next year, analysts expect an EPS growth of 12.59% and a revenue growth 46.36% for PRCT